CA3060251A1 - A 1H,2H,3H,4H,6H,7H, 1 1bHpiperazino[2,1-a]isoquinoline VMAT2 Inhibitor Compound and Compositions Thereof - Google Patents
A 1H,2H,3H,4H,6H,7H, 1 1bHpiperazino[2,1-a]isoquinoline VMAT2 Inhibitor Compound and Compositions Thereof Download PDFInfo
- Publication number
- CA3060251A1 CA3060251A1 CA3060251A CA3060251A CA3060251A1 CA 3060251 A1 CA3060251 A1 CA 3060251A1 CA 3060251 A CA3060251 A CA 3060251A CA 3060251 A CA3060251 A CA 3060251A CA 3060251 A1 CA3060251 A1 CA 3060251A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- piperazino
- methoxy
- pharmaceutically acceptable
- isoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XTVKTAYLFFSQAV-YLJYHZDGSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OC3CCC3)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OC3CCC3)N2C1 XTVKTAYLFFSQAV-YLJYHZDGSA-N 0.000 description 1
- DVFSEMKAYDMVAP-DOGRWBMSSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(C3)C3(F)F)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(C3)C3(F)F)N2C1 DVFSEMKAYDMVAP-DOGRWBMSSA-N 0.000 description 1
- SJZUJIZNMCNZGG-NVXWUHKLSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(F)(F)F)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC(F)(F)F)N2C1 SJZUJIZNMCNZGG-NVXWUHKLSA-N 0.000 description 1
- KDXZEBQAKJGNQX-UYAOXDASSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CC3)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCC3CC3)N2C1 KDXZEBQAKJGNQX-UYAOXDASSA-N 0.000 description 1
- VTAOPLYMQRUKAD-SJLPKXTDSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCC(F)(F)F)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCC(F)(F)F)N2C1 VTAOPLYMQRUKAD-SJLPKXTDSA-N 0.000 description 1
- ICIKYPUVZPRHMT-UYAOXDASSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC#N)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCC#N)N2C1 ICIKYPUVZPRHMT-UYAOXDASSA-N 0.000 description 1
- XCJFEGSDQRERME-UYAOXDASSA-N CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCF)N2C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(c(CC2)c3)cc(OC)c3OCCCCF)N2C1 XCJFEGSDQRERME-UYAOXDASSA-N 0.000 description 1
- DGXXTRVTYWNWLO-IEBWSBKVSA-N CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCCC(F)(F)F)N3C1 Chemical compound CC(C)C[C@H]1N(C)C[C@H](c(cc2OC)c(CC3)cc2OCCCC(F)(F)F)N3C1 DGXXTRVTYWNWLO-IEBWSBKVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US62/487,413 | 2017-04-19 | ||
| US201862652837P | 2018-04-04 | 2018-04-04 | |
| US62/652,837 | 2018-04-04 | ||
| PCT/US2018/028031 WO2018195121A1 (en) | 2017-04-19 | 2018-04-17 | Vmat2 inhibitor compounds and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3060251A1 true CA3060251A1 (en) | 2018-10-25 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3060251A Pending CA3060251A1 (en) | 2017-04-19 | 2018-04-17 | A 1H,2H,3H,4H,6H,7H, 1 1bHpiperazino[2,1-a]isoquinoline VMAT2 Inhibitor Compound and Compositions Thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (enExample) |
| EP (1) | EP3612532B1 (enExample) |
| JP (1) | JP7170662B2 (enExample) |
| KR (1) | KR20190140968A (enExample) |
| CN (1) | CN110770236B (enExample) |
| AU (1) | AU2018254429A1 (enExample) |
| BR (1) | BR112019021853A2 (enExample) |
| CA (1) | CA3060251A1 (enExample) |
| CL (1) | CL2019002919A1 (enExample) |
| CO (1) | CO2019011604A2 (enExample) |
| ES (1) | ES2971230T3 (enExample) |
| JO (1) | JOP20190239A1 (enExample) |
| MA (1) | MA50145A (enExample) |
| MX (1) | MX2019012336A (enExample) |
| PE (1) | PE20191784A1 (enExample) |
| TW (1) | TW201841913A (enExample) |
| WO (1) | WO2018195121A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230170136A (ko) | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| JOP20200298A1 (ar) * | 2018-06-14 | 2020-11-22 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020086765A1 (en) * | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| PE20240822A1 (es) | 2021-03-22 | 2024-04-18 | Neurocrine Biosciences Inc | Inhibidores de vmat2 y metodos de uso |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| JP2008509925A (ja) * | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9012471B2 (en) * | 2008-04-11 | 2015-04-21 | The Trustees Of Columbia University In The City Of New York | Glucose metabolism modulating compounds |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2784830C (en) * | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2014043866A1 (zh) | 2012-09-19 | 2014-03-27 | 中国科学院福建物质结构研究所 | 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途 |
| US9782398B2 (en) | 2014-02-07 | 2017-10-10 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
| KR102586138B1 (ko) | 2015-02-06 | 2023-10-05 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법 |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4223369A1 (en) | 2016-12-22 | 2023-08-09 | Incyte Corporation | Immunomodulator compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en not_active Ceased
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko not_active Withdrawn
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7170662B2 (ja) | 2022-11-14 |
| US11040970B2 (en) | 2021-06-22 |
| CN110770236B (zh) | 2023-03-24 |
| MX2019012336A (es) | 2020-07-14 |
| PE20191784A1 (es) | 2019-12-24 |
| KR20190140968A (ko) | 2019-12-20 |
| AU2018254429A1 (en) | 2019-11-07 |
| EP3612532B1 (en) | 2023-12-13 |
| EP3612532A1 (en) | 2020-02-26 |
| MA50145A (fr) | 2020-07-29 |
| CL2019002919A1 (es) | 2020-01-17 |
| EP3612532C0 (en) | 2023-12-13 |
| WO2018195121A1 (en) | 2018-10-25 |
| BR112019021853A2 (pt) | 2020-05-26 |
| TW201841913A (zh) | 2018-12-01 |
| CO2019011604A2 (es) | 2019-10-31 |
| CN110770236A (zh) | 2020-02-07 |
| JP2020517607A (ja) | 2020-06-18 |
| JOP20190239A1 (ar) | 2019-10-09 |
| US20200131173A1 (en) | 2020-04-30 |
| ES2971230T3 (es) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3612532B1 (en) | Vmat2 inhibitor compounds and compositions thereof | |
| JP7155206B2 (ja) | 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤 | |
| EP4691560A2 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| JP2020500875A (ja) | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 | |
| US20240025852A1 (en) | T-type calcium channel modulators and methods of use thereof | |
| US20250215011A1 (en) | T-type calcium channel modulators comprising a diazaspiroheptane core and methods of use thereof | |
| HK1248116B (en) | Vmat2 inhibitors for treating neurological diseases or disorders | |
| BR112017027839B1 (pt) | Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230412 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241001 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250411 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250411 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250523 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250523 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |